Humacyte, Inc.
HUMA
$0.58
-$0.02-2.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 159.29% | 289.94% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 159.29% | 289.94% | -- | -- | -- |
| Cost of Revenue | 0.16% | 0.29% | -10.83% | -13.79% | -2.85% |
| Gross Profit | 1.46% | 1.52% | 13.13% | 15.57% | 3.82% |
| SG&A Expenses | 1.30% | 7.12% | 20.82% | 27.16% | 32.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.47% | 2.03% | -3.69% | -4.92% | 4.84% |
| Operating Income | 0.70% | -0.70% | 5.47% | 6.31% | -4.07% |
| Income Before Tax | -64.91% | -25.65% | 72.54% | 75.82% | 58.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.91% | -25.65% | 72.54% | 75.82% | 58.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.91% | -25.65% | 72.54% | 75.82% | 58.00% |
| EBIT | 0.70% | -0.70% | 5.47% | 6.31% | -4.07% |
| EBITDA | 0.67% | -0.68% | 5.98% | 6.89% | -4.29% |
| EPS Basic | -11.63% | 14.45% | 85.05% | 83.52% | 65.29% |
| Normalized Basic EPS | 38.35% | 35.77% | 49.10% | 37.91% | 25.41% |
| EPS Diluted | -11.68% | 15.28% | 84.86% | 83.34% | 65.17% |
| Normalized Diluted EPS | 38.34% | 35.76% | 49.12% | 37.93% | 25.43% |
| Average Basic Shares Outstanding | 45.68% | 40.46% | 33.42% | 27.07% | 22.78% |
| Average Diluted Shares Outstanding | 45.61% | 40.39% | 33.48% | 27.13% | 22.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |